Hikma Pharmaceuticals: executive compensation 2025
Hikma Pharmaceuticals paid Said Darwazah $3.08m for 2025: $1.22m fixed, a $948k bonus and $912k from LTIP awards.
Said Darwazah, Executive Chairman
Mazen Darwazah, Executive Vice Chairman
Pay by element
| USD | Said Darwazah | Mazen Darwazah | Riad Mishlawi | Khalid Nabilsi |
|---|---|---|---|---|
| Salary | $1.04m | $830k | $1.15m | $38k |
| Benefits | $108k | $100k | $577k | $2k |
| Pension | $69k | $67k | $115k | $4k |
| Total fixed | $1.22m | $997k | $1.84m | $44k |
| Annual bonus | $948k | $1.22m | $229k | $0 |
| LTIP vesting | $912k | $1.04m | $1.05m | $0 |
| Total | $3.08m | $3.26m | $3.12m | $44k |
| Previous year | $3.54m | $2.90m | $3.51m | n/a |
Bonus scorecard: Annual Bonus Plan
Said Darwazah: maximum 200% of salary. Mazen Darwazah: maximum 200% of salary. Riad Mishlawi: maximum 200% of salary. Khalid Nabilsi: maximum 175% of salary. Scorecard result: 91.2% of salary.
| Measure | Weighting | Threshold | Target | Maximum | Result | Paid, points of the total |
|---|---|---|---|---|---|---|
| Core revenue | 30% | $2,991m | $3,323m | $3,656m | $3,349m | 32.3 |
| Core operating profit | 50% | $682m | $758m | $834m | $741m | 38.8 |
| Enhancing strategic execution | 10% | Strategy executed | Threshold plus governance improved and leadership strengthened | Target plus research and development capability maximised | n/a | 5 |
| Sustainability | 10% | n/a | n/a | n/a | Advanced | 15 |
Deferral: Half of the bonus is paid in cash and half is deferred into shares for three years.
LTIP: 2023 Long Term Incentive Plan award (performance period 2023 to 2025)
Vested at 62.56% of the maximum.
| Measure | Weighting | Result |
|---|---|---|
| Core compound earnings per share growth | 30% | 18.75% |
| Share of revenue from new business over three years | 30% | 30% |
| Relative shareholder return against the FTSE 50 to 150 | 20% | 0% |
| Succession planning | 10% | 7.56% |
| Good water management at all Hikma sites in the Middle East and North Africa | 10% | 6.25% |
Notes
Hikma reports in US dollars, in whole dollars. Said Darwazah is Executive Chairman and signs the report as Executive Chairman and CEO, so he is listed first; Riad Mishlawi was CEO until 15 December 2025. The scorecard shown is the Executive Chairman's. Its results are shown as a percentage of salary, where the most that can be paid is 200%, so the 91.2% total is about 46% of the maximum. The Executive Vice Chairman and the former CEO have different scorecards. For Riad Mishlawi the formula result was 99.7% of salary, but the committee reduced his bonus to 20% of salary, saying this better reflected his contribution over the period. Khalid Nabilsi joined the board on 15 December 2025, so his figures cover only the end of the year and he received no 2025 bonus. The LTIP awards column in the pay table is an award of shares that vests two years after it is granted (the report calls it EIP element B), counted in the year it vests. The 2023 long-term incentive plan result listed here is reported separately by Hikma and has no column in the pay table. The report gives no percentile pay ratios, only one ratio of CEO pay to the average group employee of 15 to 1.
Source: Hikma Pharmaceuticals's annual report for 2025 (pay table page 132, bonus scorecard page 133-136, LTIP awards page 137, pay ratio page 147).
CEO pay at every companyRead from the company's own annual report and checked by arithmetic: pay adds up for Said Darwazah; pay adds up for Mazen Darwazah; pay adds up for Riad Mishlawi; pay adds up for Khalid Nabilsi; scorecard weightings add to 100%; measure payouts add up to the stated outcome. Figures are as the company reported them, in its own currency. How it works.